Brequinar (BioDeep_00000176818)
Secondary id: BioDeep_00000015286
human metabolite blood metabolite
代谢物信息卡片
6-fluoro-2-(2-fluoro-1,1-Biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid
化学式: C23H15F2NO2 (375.10707940000003)
中文名称: 布喹那
谱图信息:
最多检出来源 Homo sapiens(blood) 4%
分子结构信息
SMILES: CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O
InChI: InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
描述信息
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
C471 - Enzyme Inhibitor > C2169 - Dihydroorotate Dehydrogenase Inhibitor
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents
D000970 - Antineoplastic Agents
D004791 - Enzyme Inhibitors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:177387
- KEGG: C77324
- PubChem: 57030
- HMDB: HMDB0249377
- DrugBank: DB03523
- ChEMBL: CHEMBL38434
- Wikipedia: Brequinar
- CAS: 96187-53-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Qiubo Ding, Weinan Tang, Xianglong Li, Yuanzhen Ding, Xinnan Chen, Wenmin Cao, Xinwu Wang, Wenjing Mo, Zhigui Su, Qing Zhang, Hongqian Guo. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer.
Journal of controlled release : official journal of the Controlled Release Society.
2023 11; 363(?):221-234. doi:
10.1016/j.jconrel.2023.09.024. [PMID: 37717657] - Yang Chen, Yanchen Guo, Hao Chang, Zebu Song, Zhi Wei, Zhao Huang, Zezhong Zheng, Guihong Zhang, Yankuo Sun. Brequinar inhibits African swine fever virus replication in vitro by activating ferroptosis.
Virology journal.
2023 10; 20(1):242. doi:
10.1186/s12985-023-02204-x. [PMID: 37875895] - Chengheng Liao, Cherise Ryan Glodowski, Cheng Fan, Juan Liu, Kevin R Mott, Akash Kaushik, Hieu Vu, Jason W Locasale, Samuel K McBrayer, Ralph J DeBerardinis, Charles M Perou, Qing Zhang. Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
Cancer research.
2022 02; 82(4):665-680. doi:
10.1158/0008-5472.can-21-2745. [PMID: 34911787] - Yajie Yu, Jane Ding, Shunqin Zhu, Ahmet Alptekin, Zheng Dong, Chunhong Yan, Yunhong Zha, Han-Fei Ding. Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Cell death & disease.
2021 08; 12(9):821. doi:
10.1038/s41419-021-04120-w. [PMID: 34462431] - Chao Mao, Xiaoguang Liu, Yilei Zhang, Guang Lei, Yuelong Yan, Hyemin Lee, Pranavi Koppula, Shiqi Wu, Li Zhuang, Bingliang Fang, Masha V Poyurovsky, Kellen Olszewski, Boyi Gan. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
Nature.
2021 05; 593(7860):586-590. doi:
10.1038/s41586-021-03539-7. [PMID: 33981038] - Yao Li, Li Yi, Sipeng Cheng, Yongshan Wang, Jiongjiong Wang, Jing Sun, Quan Zhang, Xiulong Xu. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
The Journal of general virology.
2021 03; 102(3):. doi:
10.1099/jgv.0.001534. [PMID: 33416466] - Ana R Coelho, Paulo J Oliveira. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
European journal of clinical investigation.
2020 Oct; 50(10):e13366. doi:
10.1111/eci.13366. [PMID: 32735689] - Petter I Andersen, Klara Krpina, Aleksandr Ianevski, Nastassia Shtaida, Eunji Jo, Jaewon Yang, Sandra Koit, Tanel Tenson, Veijo Hukkanen, Marit W Anthonsen, Magnar Bjoras, Magnus Evander, Marc P Windisch, Eva Zusinaite, Denis E Kainov. Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine.
Viruses.
2019 10; 11(10):. doi:
10.3390/v11100964. [PMID: 31635418] - Shi-Fang Li, Mei-Jiao Gong, Yue-Feng Sun, Jun-Jun Shao, Yong-Guang Zhang, Hui-Yun Chang. Antiviral activity of brequinar against foot-and-mouth disease virus infection in vitro and in vivo.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2019 Aug; 116(?):108982. doi:
10.1016/j.biopha.2019.108982. [PMID: 31146110] - Godefridus J Peters. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Nucleosides, nucleotides & nucleic acids.
2018; 37(12):666-678. doi:
10.1080/15257770.2018.1508692. [PMID: 30663496] - Laila Castro Schnellrath, Clarissa R Damaso. Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture.
International journal of antimicrobial agents.
2011 Nov; 38(5):435-41. doi:
10.1016/j.ijantimicag.2011.07.002. [PMID: 21840180] - Elke Zameitat, Gerald Freymark, Cornelia D Dietz, Monika Löffler, Michael Bölker. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Applied and environmental microbiology.
2007 May; 73(10):3371-9. doi:
10.1128/aem.02569-06. [PMID: 17369345] - K Kobayashi, A Nakashima, H Nagata, H Nakajima, K Yamaguchi, S Sato, I Miki. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.].
2001 Jan; 50(1):24-31. doi:
10.1007/s000110050720. [PMID: 11235018] - D S Ko, A Bartholomew, A J Poncelet, D H Sachs, C Huang, A LeGuern, K I Abraham, R B Colvin, S Boskovic, H Z Hong, S L Wee, H J Winn, A B Cosimi. Demonstration of multilineage chimerism in a nonhuman primate concordant xenograft model.
Xenotransplantation.
1998 Nov; 5(4):298-304. doi:
10.1111/j.1399-3089.1998.tb00041.x. [PMID: 9915258] - H A Burris, E Raymond, A Awada, J G Kuhn, T J O'Rourke, J Brentzel, W Lynch, S Y King, T D Brown, D D Von Hoff. Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
Investigational new drugs.
1998; 16(1):19-27. doi:
10.1023/a:1016066529642. [PMID: 9740540] - A S Joshi, S Y King, B A Zajac, L Makowka, L S Sher, B D Kahan, A H Menkis, C R Stiller, B Schaefle, D M Kornhauser. Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients.
Journal of clinical pharmacology.
1997 Dec; 37(12):1121-8. doi:
10.1002/j.1552-4604.1997.tb04296.x. [PMID: 9506007] - A E Levy, J W Alexander. The significance of timing of additional short-term immunosuppression in the donor-specific transfusion/cyclosporine-treated rat.
Transplantation.
1996 Jul; 62(2):262-6. doi:
10.1097/00007890-199607270-00019. [PMID: 8755826] - E S Cleaveland, D W Zaharevitz, J A Kelley, K Paull, D A Cooney, H Ford. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Biochemical and biophysical research communications.
1996 Jun; 223(3):654-9. doi:
10.1006/bbrc.1996.0950. [PMID: 8687451] - J F Dunn, J Hatch, A Precht, M Hart, S Li. Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared with azathioprine.
Transplantation proceedings.
1996 Apr; 28(2):955-7. doi:
NULL. [PMID: 8623479] - D V Cramer. Brequinar sodium.
Transplantation proceedings.
1996 Apr; 28(2):960-3. doi:
NULL. [PMID: 8623481] - M Wang, X Qu, S M Stepkowski, T C Chou, B D Kahan. Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus.
Transplantation.
1996 Feb; 61(3):458-64. doi:
10.1097/00007890-199602150-00025. [PMID: 8610361] - S Dasgupta, D M Timby, G N Lam. Determination of brequinar in rat plasma by direct deproteinization and reversed-phase high-performance liquid chromatography with ultraviolet absorbance detection.
Journal of chromatography. B, Biomedical applications.
1995 Nov; 673(1):107-12. doi:
10.1016/0378-4347(95)00249-i. [PMID: 8925063] - B D Kahan. Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation.
Transplantation proceedings.
1995 Feb; 27(1):33-6. doi:
NULL. [PMID: 7879019] - D V Cramer. Brequinar sodium.
Pediatric nephrology (Berlin, Germany).
1995; 9 Suppl(?):S52-5. doi:
10.1007/bf00867685. [PMID: 7492488] - A C Buzaid, G Pizzorno, J C Marsh, T S Ravikumar, J R Murren, M Todd, R K Strair, W J Poo, W N Hait. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Cancer chemotherapy and pharmacology.
1995; 36(5):373-8. doi:
10.1007/bf00686185. [PMID: 7634378] - M Ferraresso, R Knight, Y Tu, S M Stepkowski, B D Kahan. Triple combination of cyclosporine, brequinar, and rapamycin prolongs kidney allograft survival in the mongrel dog.
Transplantation proceedings.
1994 Oct; 26(5):3028. doi:
NULL. [PMID: 7940953] - C A Cosenza, D V Cramer, P J Tuso, F A Chapman, H K Wang, L Makowka. Combination therapy with Brequinar sodium and cyclosporine synergistically prolongs hamster-to-rat cardia xenograft survival.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
1994 May; 13(3):489-97. doi:
NULL. [PMID: 8061026] - H Shirwan, C A Cosenza, H K Wang, G D Wu, L Makowka, D V Cramer. Prevention of orthotopic liver allograft rejection in rats with a short-term brequinar sodium therapy. Analysis of intragraft cytokine gene expression.
Transplantation.
1994 Apr; 57(7):1072-80. doi:
10.1097/00007890-199404000-00016. [PMID: 8165706] - S Y King, A M Agra, H S Shen, C L Chi, D B Adams, V E Currie, J R Bertino, H J Pieniaszek, C Y Quon. Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.
Cancer chemotherapy and pharmacology.
1994; 35(2):101-8. doi:
10.1007/bf00686630. [PMID: 7987984] - C A Cosenza, D V Cramer, G Eiras-Hreha, E Cajulis, H K Wang, L Makowka. The synergism of brequinar sodium and cyclosporine used in combination to prevent cardiac allograft rejection in the rat.
Transplantation.
1993 Sep; 56(3):667-72. doi:
10.1097/00007890-199309000-00032. [PMID: 8212165] - K Tamura, J Woo, M T Bakri, A W Thomson. Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells.
Immunology.
1993 Aug; 79(4):587-93. doi:
NULL. [PMID: 8406583] - C G Groth, S Ohlman, G Gannedahl, B G Ericzon. New immunosuppressive drugs in transplantation.
Transplantation proceedings.
1993 Aug; 25(4):2681-3. doi:
NULL. [PMID: 7689274] - D V Cramer, F A Chapman, L Makowka. Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium.
Transplantation proceedings.
1993 Jun; 25(3 Suppl 2):23-8. doi:
NULL. [PMID: 8516938] - G Eiras-Hreha, D V Cramer, C Cosenza, F A Chapman, L Mills, E Cajulis, D Hill, E Jones, I Zajac, B Jaffee. Brequinar sodium: monitoring immunosuppressive activity.
Transplantation proceedings.
1993 Jun; 25(3 Suppl 2):32-6. doi:
NULL. [PMID: 8516940] - N Murase, T E Starzl, A J Demetris, L Valdivia, M Tanabe, D Cramer, L Makowka. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs.
Transplantation.
1993 Apr; 55(4):701-7; discussion 707. doi:
10.1097/00007890-199304000-00003. [PMID: 7682735] - M de Forni, G G Chabot, J P Armand, X Fontana, G Recondo, C Domenge, P Carde, M Barbu, A Gouyette. Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.
European journal of cancer (Oxford, England : 1990).
1993; 29A(7):983-8. doi:
10.1016/s0959-8049(05)80206-0. [PMID: 8499153] - D V Cramer, F A Chapman, B D Jaffee, I Zajac, G Hreha-Eiras, C Yasunaga, G D Wu, L Makowka. The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium.
Transplantation.
1992 Sep; 54(3):403-8. doi:
10.1097/00007890-199209000-00003. [PMID: 1412717] - G Pizzorno, R A Wiegand, S K Lentz, R E Handschumacher. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
Cancer research.
1992 Apr; 52(7):1660-5. doi:
. [PMID: 1551097] - D V Cramer, F A Chapman, B D Jaffee, E A Jones, M Knoop, G Hreha-Eiras, L Makowka. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.
Transplantation.
1992 Feb; 53(2):303-8. doi:
10.1097/00007890-199202010-00009. [PMID: 1531394] - G J Peters, G Schwartsmann, J C Nadal, E J Laurensse, C J van Groeningen, W J van der Vijgh, H M Pinedo. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Cancer research.
1990 Aug; 50(15):4644-9. doi:
. [PMID: 2164443] - D A Noe, E K Rowinsky, H S Shen, B V Clarke, L B Grochow, W B McGuire, A Hantel, D B Adams, M D Abeloff, D S Ettinger. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Cancer research.
1990 Aug; 50(15):4595-9. doi:
. [PMID: 2369734] - B J Aungst, J A Blake, N J Rogers, B A Dusak. Effects of plasma protein binding displacement on the pharmacokinetics, tissue and tumor concentrations and efficacy of brequinar, a highly protein-bound antitumor agent.
The Journal of pharmacology and experimental therapeutics.
1990 Apr; 253(1):230-6. doi:
NULL. [PMID: 2329509] - G J Peters, J C Nadal, E J Laurensse, E de Kant, H M Pinedo. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Biochemical pharmacology.
1990 Jan; 39(1):135-44. doi:
10.1016/0006-2952(90)90657-7. [PMID: 2153375] - G Schwartsmann, W J van der Vijgh, M B van Hennik, I Klein, J B Vermorken, P Dodion, W W ten Bokkel Huinink, G Joggi, H Gall, N Crespeigne. Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
European journal of cancer & clinical oncology.
1989 Dec; 25(12):1675-81. doi:
10.1016/0277-5379(89)90334-9. [PMID: 2632251] - E Bork, S Vest, H H Hansen. A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
European journal of cancer & clinical oncology.
1989 Oct; 25(10):1403-11. doi:
10.1016/0277-5379(89)90097-7. [PMID: 2591433] - C L Arteaga, T D Brown, J G Kuhn, H S Shen, T J O'Rourke, K Beougher, H J Brentzel, D D Von Hoff, G R Weiss. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Cancer research.
1989 Aug; 49(16):4648-53. doi:
. [PMID: 2743343]